2752-38-7

Basic information

• Product Name: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid
• Synonyms: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid
• CAS NO: 2752-38-7
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.27
• Mol File: 2752-38-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 469.5°C at 760 mmHg
• Flash Point: 237.7°C
• Appearance: /
• Density: 1.267g/cm³
• Vapor Pressure: 1.28E-09mmHg at 25°C
• Refractive Index: 1.586
• CAS DataBase Reference: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid(2752-38-7)
• EPA Substance Registry System: (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid(2752-38-7)

Safety Data

• Hazardous Substances Data: 2752-38-7(Hazardous Substances Data)

Usage

General Description

(S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid, also known as Modafinil, is a pharmaceutical compound used primarily to treat narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea. It is also used off-label for cognitive enhancement and to improve wakefulness in individuals with fatigue-related conditions. Modafinil works by stimulating the central nervous system, specifically by increasing the release of dopamine in the brain. This results in heightened arousal and alertness, as well as improved cognitive function and memory. The drug has a low potential for abuse and addiction, and is generally considered to be safe when taken as prescribed. However, it can cause side effects such as headache, nausea, and insomnia, and should be used with caution in individuals with a history of heart problems or mental health issues.

InChI:InChI=1/C13H15NO3/c15-12(9-10-5-2-1-3-6-10)14-8-4-7-11(14)13(16)17/h1-3,5-6,11H,4,7-9H2,(H,16,17)/t11-/m0/s1

Upstream product

• 103-80-0 phenylacetyl chloride 
• 147-85-3 L-proline 
• 103-82-2 phenylacetic acid 
• 609-36-9 rac-Pro-OH 
• 147-85-3 L-proline 
• 78348-56-8 (2S)-1-(phenylacetyl)pyrrolidine-2-carboxylic acid methyl ester 
• 16652-71-4 benzyl (2S)-2-pyrrolidinecarboxylate hydrochloride 
• 88105-65-1 (S)-1-phenylacetyl-pyrrolidine-2-carboxylic acid benzyl ester 

Downstream Products

• 1312611-08-7 C₁₉H₂₁BN₂O₄ 
• 1312611-12-3 C₂₃H₂₃N₃O₂ 
• 1312609-11-2 C₃₅H₄₁N₅O₆ 
• 1312609-12-3 C₃₆H₃₆N₄O₄ 
• 1312611-09-8 C₃₄H₃₅N₃O₄ 
• 1312611-10-1 C₂₉H₂₇N₃O₂ 
• 1312609-13-4 C₄₂H₄₀N₄O₄ 
• 1312609-05-4 C₃₉H₃₉N₅O₅ 
• 1312611-00-9 C₂₆H₂₄N₄O₅ 
• 1312611-01-0 C₂₆H₂₆N₄O₃ 
• 1246470-80-3 C₃₉H₃₈N₆O₄ 
• 1313744-67-0 (2S,2'S)-N,N'-(4,4'-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-(2-phenylacetyl)pyrrolidine-2-carboxamide) 
• 1313744-14-7 (2S,2'S)-N,N'-(4,4'-(1H-pyrazole-3,5-diyl)bis(4,1-phenylene))bis(1-(2-phenylacetyl)pyrrolidine-2-carboxamide) 
• 1219630-12-2 (2S,2’S)-N,N’-(1,2-ethynediyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide) 

Relevant articles and documents

N-phenylacetyl-L-proline preparation method

The invention discloses an N-phenylacetyl-L-proline preparation method which includes the steps: dripping phenyl acetyl chloride and acid-binding agents into an organic solvent dissolved L-proline atlow temperature; adding a phase transfer catalyst, perfo

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Synthesis and antiamnesic activity of a series of N-acylprolyl-containing dipeptides

Eaters and amides of a series of N-acylprolyl-containing dipeptides were synthesized. It was established that these substances possess the ability to prevent memory decline evoked by maximal electroshock (MES) in a passive avoidance step-through paradigm. These N-acylprolyl-containing dipeptides were designed as analogues of pyroglutamyl-containing dipeptides, which we previously demonstrated to be highly active nootropics. Among the structure-activity relationships explored were the effect of N-acylsubstitution size, C-terminal substitution and the nature of the second amino acid. The optimal N-acyl moiety was the N-phenyl-acetyl group, while the optimal C-terminal substitution-esters were those derived from low alkyl alcohols. The optimal second amino acids were Asp, Glu or their fragments, Gly, β-Ala, GABA. Compound 1 (N-phenylacetylprolylglycine ethyl eater) was selected for further evalution in impaired cognitive functions. It was supposed that esters and unsubstituted amides of N-acylprolylglycines are prodrugs, which convert to the bioactive cyclo-(Pro-Gly) by virtue of enzymatic or chemical lability within the body.